Abstract: Traditionally, biobanks were used purely for “back-end” research to understand diseases. However, a major study of Geisinger’s MyCode initiative found that 3.4% of participants carried serious genomic risks for cancer or heart disease. The shocking part? 88% of these people had no idea they were at risk. Even among those who already showed symptoms, many had never been offered a genetic test. This “gap” in care is the primary reason why biobanks are shifting from being just data archives to becoming active tools for clinical prevention.
To bridge this gap, researchers screened 175,500 individuals for a specific list of 81 “actionable” genes, DNA sequences that we know how to treat or manage. When a high-risk variant was found, the team alerted the individuals, allowing them to pursue life-saving screenings or surgeries before a crisis occurred. To fund this massive effort, Geisinger partnered with industry leaders like Regeneron, proving that large-scale genomic screening is possible when health systems and researchers share resources. The goal now is to turn this into a “learning health system” where genetic data is a standard part of medical management for everyone.
For more information: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831654?resultClick=24